DOYLESTOWN, Pa., Oct. 26 /PRNewswire-FirstCall/ -- Quigley Pharma, a wholly-owned subsidiary of Quigley Corporation , announced today the completion of an animal model study of its naturally derived compound QR-442. The murine experimental autoimmune encephalomyelitis (EAE) is an animal model for multiple sclerosis.
The study included administering QR-442 to affected mice three times, at days, one, three and seven. The treated mice showed a delayed onset of disease and a significantly lower disease severity than those left untreated.
“We are encouraged by the study results,” said Dr. Richard Rosenbloom, Chief Operating Officer, Quigley Pharma. “A follow up study will begin immediately with more frequent dosing in an effort to see the drug’s full potential.”
According to the National Multiple Sclerosis Society, nearly 400,000 Americans have multiple sclerosis, and up to 2.5 million worldwide may be affected by the chronic disease of the brain and spinal cord.
The Quigley Corporation is the leading developer and marketer of diversified health products. The company’s proven success in launching first-in-category health solutions supports the Pharma subsidiary in its efforts to develop strong pharmaceutical compounds targeting diverse conditions such as diabetes and rheumatoid arthritis with naturally derived compounds and botanicals.
The Quigley Corporation makes no representation that the U.S. Food and Drug Administration or any other regulatory agency will grant an IND or take any other action to allow the aforementioned compound to be studied or marketed. Furthermore, no claim is made that the potential medicine discussed here is safe, effective, or approved by the Food and Drug Administration.
About The Quigley Corporation
The Quigley Corporation is a diversified natural health medical science company. Its Cold Remedy segment is a leading marketer and manufacturer of the COLD-EEZE(R) family of lozenges, gums and sugar free tablets clinically proven to cut the common cold nearly in half. COLD-EEZE customers include leading national wholesalers and distributors, as well as independent and chain food, drug and mass merchandise stores and pharmacies. The Quigley Corporation has four (4) wholly owned subsidiaries. Darius International markets health and wellness products through its wholly owned subsidiary, InnerLight Inc. Quigley Manufacturing Inc. consists of two FDA approved facilities to manufacture COLD-EEZE(R) lozenges as well as fulfill other contract manufacturing opportunities. Quigley Pharma Inc. (http://www.QuigleyPharma.com) conducts research in order to develop and commercialize a pipeline of patented botanical and naturally derived prescription drugs.
Certain statements in this press release are “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995 and involve known and unknown risk, uncertainties and other factors that may cause the company’s actual performance or achievements to be materially different from the results, performance or achievements expressed or implied by the forward-looking statement. Factors that impact such forward-looking statements include, among others, changes in worldwide general economic conditions, changes in interest rates, government regulations, and worldwide competition.
CONTACT: Media Investor Relations Karen Pineman Carl Hymans G.S. Schwartz & Co. G.S. Schwartz & Co. 212.725.4500 212.725.4500 kpineman@schwartz.comcarlh@schwartz.com
Quigley Pharma
CONTACT: press, Karen Pineman, kpineman@schwartz.com, or investors, CarlHymans, carlh@schwartz.com, both of G.S. Schwartz & Co., +1-212-725-4500,for The Quigley Corporation
